Emergent Broadens Bioterror Offering In $125m Sanofi Smallpox Vaccine Buy
Sanofi's divestment of its ACAM200 smallpox vaccine frees it to focus on "current and emerging" infectious disease jabs - while expanding Emergent BioSolutions adds to its anti-bioterror product offering.
You may also be interested in...
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.